Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 102Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Ovarian Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms, Male 6Neoplasms 5Glioblastoma 5Central Nervous System Neoplasms 5Prostatic Neoplasms 4Gliosarcoma 4Inflammatory Breast Neoplasms 3Glioma 3Brain Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Glioma, Subependymal 2Fallopian Tube Neoplasms 2Ependymoma 2Breast Cancer Female 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Risk Reduction Behavior 1

Interventions

mirabegron 1bicalutamide 1Tamoxifen 1Sugars 1Sodium Chloride 1Pentosan Sulfuric Polyester 1Dutasteride 1Doxazosin 1Celecoxib 1Capsules 1Botulinum Toxins, Type A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lower Urinary Tract Symptoms × Tamoxifen × Clear all
NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

CHU de Quebec-Universite Laval

Phase 2 Completed
60 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡